Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10894 |
CSF1R-IN-1
|
c-Fms | Tyrosine Kinase/Adaptors |
CSF1R-IN-1 是一种 CSF1R 抑制剂 (IC50:0.5 nM)。 | |||
T13194 |
CSF1R-IN-2
|
c-Fms; c-Met/HGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
CSF1R-IN-2 是一种口服具有活力的、有效的 SRC,MET 和 c-FMS 抑制剂,它们的 IC50 值分别为 0.12 nM,0.14 nM 和 0.76 nM。 | |||
T72574 |
Axl/Mer/CSF1R-IN-1
|
||
Axl/Mer-IN-1 是一种 Axl/Mer 受体酪氨酸激酶 (Axl/Mer RTK) 和CSF1R 抑制剂,Kd 值均小于 0.1 μM。 | |||
T4075 |
Sulfatinib
KDR-IN-1,索凡替尼 |
VEGFR; FGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Sulfatinib (KDR-IN-1) (HMPL-012) 是一种有效且高度选择性的酪氨酸激酶抑制剂,可抑制VEGFR1/2/3,FGFR1和CSF1R,IC50范围为1 到 24 nM 之间。 | |||
T61554 | CSF1R-IN-13 | ||
CSF1R-IN-13 is a powerful CSF1R inhibitor with potential applications in researching cancer diseases [1]. CSF1R, also known as colony stimulating factor 1 receptor, is a critical growth factor that regulates various cell types, including bone marrow progenitor cells, monocytes, macrophages, and giants [1]. CSF1R-IN-13 shows promise in furthering our understanding of cancer-related disorders (WO2019134661A1, compound 32) [1]. | |||
T61893 |
CSF1R-IN-12
|
||
CSF1R-IN-12 是一种有效的集落刺激因子1受体 CSF1R 抑制剂。CSF1R-IN-12 在癌症疾病中具有研究潜力。 | |||
T62187 |
CSF1R-IN-6
|
||
CSF1R-IN-6 是一种 CSF1R 的有效抑制剂。其中 CSF-1R 表达于巨噬细胞中,巨噬细胞的存活和分化依赖于 CSF-1/CSF-1R 信号通路。CSF1R-IN-6 能够影响 TAM 和胶质瘤细胞之间炎症因子的交换。CSF1R-IN-6 对癌症疾病表现出潜在的研究价值。 | |||
T79472 |
CSF1R-IN-17
|
c-Fms | Tyrosine Kinase/Adaptors |
CSF1R-IN-17(compound 9)是一种选择性高的CSF1R拮抗剂,表现出0.2 nM的低IC50值,并能有效抑制破骨细胞的分化。 | |||
T62557 |
CSF1R-IN-14
|
||
CSF1R-IN-14 是一种异吲哚啉酮衍生物化合物,是一种 CSF1R 的有效抑制剂。其中集落刺激因子1 (CSF-1,又称巨噬细胞集落刺激因子,M-CSF) 是一种控制骨髓祖细胞、单核细胞、巨噬细胞和巨噬细胞的重要生长因子。CSF1R-IN-14 具有潜力进行癌症疾病的研究。 | |||
T21330 |
JNJ-28312141
JNJ 28312141,JNJ28312141 |
||
JNJ-28312141 is an orally active CSF1R inhibitor and a FLT3 inhibitor. JNJ-28312141 is a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth a | |||
T29542 |
AC708
AC 708,AC-708 |
||
AC708 is a small molecule CSF1R inhibitor that effectively inhibits CSF1R phosphorylation mediated by CSF-1 (IC50 = 26 nM) and IL-34 (IC50 = 33 nM). It also inhibited the activity of growth factor-dependent cells cultured in CSF-1 (IC50 = 38 nM) or IL-34 | |||
T62342 |
CSF1R-IN-4
|
||
CSF1R-IN-4 是一种 CSF-1R 的有效抑制剂。其中 CSF-1R 表达于巨噬细胞中,巨噬细胞的存活和分化依赖于 CSF-1/CSF-1R 信号通路。CSF1R-IN-4 能够影响 TAM 和胶质瘤细胞之间炎症因子的交换。CSF1R-IN-4 具有潜力进行癌症疾病的研究。 | |||
T69759 | IACS-9439 | c-Fms | Tyrosine Kinase/Adaptors |
IACS-9439是一种CSF1R抑制剂,具有高效、选择性和口服活性,Ki值仅为1 nM。适用于研究晚期实体肿瘤。 | |||
T62364 |
CSF1R-IN-5
|
||
CSF1R-IN-5 是一种 CSF1R 的有效抑制剂。其中 CSF-1R 表达于巨噬细胞中,巨噬细胞的存活和分化依赖于 CSF-1/CSF-1R 信号通路。CSF1R-IN-5 可以影响 TAM 和胶质瘤细胞之间炎症因子的交换。CSF1R-IN-5 具有潜力进行癌症疾病的研究。 | |||
T12505 | PLX5622 hemifumarate | c-Fms | Tyrosine Kinase/Adaptors |
PLX5622 hemifumarate 是高度选择性的、能透过血脑屏障的、具有口服活性的 CSF1R 抑制剂,IC50值为 0.016 μM,Ki 值为 5.9 nM,可用于病程发展前和过程中,扩大和特异性的小胶质细胞的消除。PLX5622 hemifumarate 具有较理想的药代动力学特性。 | |||
T76786 | Cabiralizumab | ||
Cabiralizumab (FPA 008) 是一种抗 CSF1R 单克隆抗体 (MAb)。Cabiralizumab 可增强 T 细胞浸润和抗肿瘤 T 细胞免疫反应。Cabiralizumab 抑制破骨细胞的活化并阻止骨质破坏,可用于类风湿性关节炎 (RA) 的研究。Cabiralizumab 可与 Nivolumab 结合用于肺癌研究。 | |||
T70444 |
Edicotinib HCl
|
||
Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tum... | |||
T71400 |
Quizartinib HCl
|
||
Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell pro... |